In this issue:
Ropeginterferon α-2b for essential thrombocythaemia
Inotuzumab ozogamicin then blinatumomab in elderly newly diagnosed B-cell ALL
Third-generation TKIs + azacitidine in CML in myeloid blast phase
Disease risk, not remission status, determines transplant outcomes in AML
Ixazomib decreases chronic GVHD risk: identification of biomarkers
AI-based quantitative bone marrow pathology analysis for MPNs
Alemtuzumab as conditioning for SCT
Thrombopoietin receptor agonists for SLE/antiphospholipid syndromerelated immune thrombocytopenia
Narsoplimab for SCT-associated thrombotic microangiopathy
Upfront and salvage haploidentical SCT for severe aplastic anaemia
Please login below to download this issue (PDF)